JP2008503207A5 - - Google Patents

Download PDF

Info

Publication number
JP2008503207A5
JP2008503207A5 JP2007515398A JP2007515398A JP2008503207A5 JP 2008503207 A5 JP2008503207 A5 JP 2008503207A5 JP 2007515398 A JP2007515398 A JP 2007515398A JP 2007515398 A JP2007515398 A JP 2007515398A JP 2008503207 A5 JP2008503207 A5 JP 2008503207A5
Authority
JP
Japan
Prior art keywords
antiviral
pharmaceutical composition
nucleic acid
acid molecule
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008503207A (ja
JP4776620B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018778 external-priority patent/WO2005118627A2/en
Publication of JP2008503207A publication Critical patent/JP2008503207A/ja
Publication of JP2008503207A5 publication Critical patent/JP2008503207A5/ja
Application granted granted Critical
Publication of JP4776620B2 publication Critical patent/JP4776620B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007515398A 2004-06-01 2005-05-27 グリフィスシン、グリコシル化耐性グリフィスシン、ならびに関連する抱合体、組成物、核酸、ベクター、宿主細胞、製造方法および使用方法 Expired - Lifetime JP4776620B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57605604P 2004-06-01 2004-06-01
US60/576,056 2004-06-01
PCT/US2005/018778 WO2005118627A2 (en) 2004-06-01 2005-05-27 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use

Publications (3)

Publication Number Publication Date
JP2008503207A JP2008503207A (ja) 2008-02-07
JP2008503207A5 true JP2008503207A5 (enExample) 2008-06-19
JP4776620B2 JP4776620B2 (ja) 2011-09-21

Family

ID=35463427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515398A Expired - Lifetime JP4776620B2 (ja) 2004-06-01 2005-05-27 グリフィスシン、グリコシル化耐性グリフィスシン、ならびに関連する抱合体、組成物、核酸、ベクター、宿主細胞、製造方法および使用方法

Country Status (9)

Country Link
US (2) US7884178B2 (enExample)
EP (1) EP1740605B1 (enExample)
JP (1) JP4776620B2 (enExample)
AU (1) AU2005250429B2 (enExample)
CA (1) CA2567728C (enExample)
IL (1) IL179236A (enExample)
NZ (1) NZ551375A (enExample)
WO (1) WO2005118627A2 (enExample)
ZA (1) ZA200609573B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064844A2 (en) 2005-12-01 2007-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anti-viral griffithsin compounds, compositions, and methods of use
JP5251143B2 (ja) * 2007-07-30 2013-07-31 宇部興産株式会社 多価アルコールおよびその製造方法
EP2571898B1 (en) 2010-05-21 2021-07-21 The United States of America, as represented by The Secretary, Department of Health and Human Services High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
EP2968453B1 (en) 2013-03-15 2019-12-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Stabilized single human cd4 domains and fusion proteins
EP3003388B1 (en) * 2013-06-05 2019-10-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Monomeric griffithsin tandemers
US11034736B2 (en) 2014-01-09 2021-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-viral cnidarins
US20170298100A1 (en) * 2014-10-01 2017-10-19 Cascadia Life Sciences Llc Anti-viral peptides
LT3256486T (lt) * 2015-02-10 2020-06-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Grifitzino mutantai
US10472412B2 (en) 2015-03-25 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific multivalent fusion proteins
WO2018039626A1 (en) 2016-08-25 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human single domain antibodies targeting cd16a to mediate adcc
WO2019108656A1 (en) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microbicidal composition
WO2021050727A1 (en) * 2019-09-10 2021-03-18 University Of Louisville Research Foundations,Inc. Anti-viral compositions and methods of making and using
EP4108251A1 (en) 2021-06-22 2022-12-28 Solmic Biotech GmbH Griffithsin for use in a method of preventing or treating infections with respiratory viruses
KR20240169648A (ko) 2022-03-24 2024-12-03 다니스코 유에스 인크. 렉틴의 산업적 규모의 생산 및 회수를 위한 조성물 및 방법
WO2024064653A1 (en) 2022-09-20 2024-03-28 Dupont Nutrition Biosciences Aps Variant anti-viral polypeptides
WO2025007098A1 (en) 2023-06-30 2025-01-02 Danisco Us Inc. Recombinant fungal cells and methods thereof for industrial scale production of lectins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties

Similar Documents

Publication Publication Date Title
JP2008503207A5 (enExample)
US10442845B2 (en) Interferon analogs
Van der Strate et al. Antiviral activities of lactoferrin
Wills Clinical pharmacokinetics of interferons
JP2023162283A5 (enExample)
US6361769B1 (en) Stimulation of host defense mechanisms against viral challenges
JP2001520238A5 (enExample)
JP2012501959A5 (enExample)
RU2447083C1 (ru) НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
JP2014111628A (ja) ウイルス融合のインヒビターのコレステロール誘導体
US20210309973A1 (en) Bacteriophage-Based Antibodies and Binders
JP2011508785A5 (enExample)
Ramos et al. Forms and methods for interferon’s encapsulation
JP2014525939A (ja) ペグインターフェロンλ1複合体
JPWO2021188576A5 (enExample)
JP2008532995A (ja) 組換え高効率複合インターフェロンの使用方法
JP2018052837A (ja) エボラウイルスワクチン
DK0871738T3 (da) Rekombinante virale pseudopartikler og deres anvendelse som vacciner eller antitumor-lægemidler
EP3892298A1 (en) Epitopes having sequence homology to coronavirus spike protein subunit and uses thereof
WO2021236045A1 (en) Vaccine for prevention of and/or immunization against sars-cov-2
CA2253902A1 (en) Stimulation of host defense mechanisms against viral challenges
WO2018038168A1 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
US20230131808A1 (en) Pegylated interferon tau and compositions and methods thereof
JP4332618B2 (ja) 抗hiv剤
JP2003514518A5 (enExample)